Supplementary Figure 9: ERBB1/2 signatures and growth factor-driven ER signatures among HER2 activating mutants and controls.

Gene expression analysis by RNA sequencing of T47D cells expressing the indicated mutants or controls was performed after 2 d of serum starvation followed by treatment with DMSO or 1 μM fulvestrant for 24 h. Six replicates were performed for each specific construct and drug condition. ERBB1/2 signaling (left panels) and growth factor−driven ER signaling (right panels) signature strengths are shown for each of the HER2 mutants and the controls, across all replicates, in cells treated with DMSO (a), fulvestrant (b), and palbociclib (c).